Ambry Genetics said today that it has launched genomic research services based on Fluidigm's BioMark HD and Access Array systems.
The services will include gene expression, SNP genotyping, and sample preparation for targeted sequencing using next-generation sequencers.
The BioMark HD System provides the sensitivity and throughput needed to study gene expression profiles down to the single-cell level, as well as high-throughput SNP genotyping and digital PCR for copy number variation and rare mutation detection.
Access Array enables high-throughput target enrichment for all of the major next-generation sequencing instruments, and allows users to simultaneously enrich multiple unique targets, such as exons, from a large number of samples, at low cost, Ambry said.
Fluidigm spokesperson Howard High told PCR Insider in an e-mail that besides Ambry, Fluidigm has other customers providing services with its products, but that Ambry's CLIA lab is "very successful and well-regarded."
High added that Ambry purchased both a BioMark HD and Access Array system, constituting "a good level of investment up front. Since [Ambry] has the ability to run some high-volume [research], then our follow-on chip and assay sales could be significant."